Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP07 in R/R AML and MCL
NCT05659732Phase 1Recruiting
- Sponsor
- PharmaEngine, Inc.
- Start
- Jul 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of PEP07 in acute myeloid leukemia (AML) and mantle cell lymphoma (MCL), sponsored by PharmaEngine, Inc. Primary endpoints: Safety and tolerability including Dose-Limiting Toxicity (DLT) at 4 weeks and Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) at 4 weeks. Started Jul 2023; status: recruiting.
02
Drugs
PEP07
03
Conditions
acute myeloid leukemia (AML)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT05659732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05659732.